- Oral presentation of Phase 1 dose escalation study of TB-403 in pediatric subjects with relapsed or refractory medulloblastoma (MB)
- Poster presentation of research findings of best therapeutic approach to target CCR8 expressed on tumor regulatory T cells to boost anti-tumor immune responses
Leuven, Belgium 9th April 2021 – 7.30 AM CET – ONCURIOUS NV, a Belgium-based biotech company focused on developing innovative oncology treatments, today announces that it will make two presentations at the upcoming AACR Virtual Annual Meeting 2021 which will take place from 9 to 14 April.
The first of these is an oral presentation of data from a Phase 1 dose escalation study of TB-403, a humanized monoclonal antibody against placental growth factor (PlGF), in pediatric cancer subjects for treatment of medulloblastoma:
Title: A Phase 1, open label, multicenter, dose escalation study of TB-403 in pediatric subjects with relapsed or refractory medulloblastoma, neuroblastoma, Ewing Sarcoma or alveolar rhabdomyosarcoma
Presented by: Dr. Giselle Sholler, Director at the Isabella Santos Foundation Solid and Rare Tumor Program, Chair at Beat Childhood Cancer Research Consortium, and Professor, Pediatric Oncology at the Levine Children’s Hospital in Charlotte, NC.
Presentation #: CT015
Session Title: Early Clinical Trials with New Anticancer Agents
Session Date and Time: Saturday 10th April from 1:30 PM to 3:30 PM US EDT
The second presentation is an e-poster presentation of preclinical data:
Title: Investigation of the best therapeutic approach to target CCR8 expressed on tumor regulatory T cells to boost anti-tumor immune responses
Authors: Heleen Roose, Elizabeth Allen, Helena Van Damme, Bruno Dombrecht, Rosa Martín-Pérez, Damya Laoui, Jo A. Van Ginderachter, Pascal Merchiers. Oncurious NV, Leuven, Belgium, Laboratory of Cellular and Molecular Immunology, Vrije Universiteit Brussel and Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium, VIB Discovery Sciences, Leuven-Ghent, Belgium.
Date and Time: The e-poster will be available on AACR’s website on Saturday 10th April at 8:30 AM US EDT (the first day of the virtual AACR Annual Meeting). The e-poster will remain available for viewing through to Monday 21st June 2021.
The abstract can be viewed here.
In February 2021, The Journal for Immunotherapy of Cancer (a BMJ journal) published a paper on the efficacy and safety of targeting CCR8 for the depletion of tumor-promoting tumor infiltrating Tregs in combination with anti-PD-1 therapy. For more information please see Oncurious press release here.